daigen bpc-157 BPC-157 | Meridian Peptides
Description
Hocaoglu, S
The riddle of nonalcoholic fatty liver disease: Progression from nonalcoholic fatty liver to nonalcoholic Steatohepatitis (in Eng)
Phase 2 trials showed up to 24% body weight reduction at the highest dose, and Phase 3 data from the TRIUMPH program pushed that number even higher, reaching 28.7% in participants with obesity and knee osteoarthritis
For a 2 mg vial, use 1 mL (gives 2 mg/mL or 2,000 mcg/mL)
For broader context on angiogenesis, tissue repair pathways, and multi-compound interactions, see our Healing & recovery research guide
